A Phase Ib/II Study of WNT974 + Encorafenib + Cetuximab in Patients With BRAF V600E-Mutant KRAS Wild-Type Metastatic Colorectal Cancer.

Autor: Tabernero J; Vall d'Hebron Hospital Campus, Vall d'Hebron Institute of Oncology (VHIO), UVic-UCC, IOB-Quiron, Barcelona, Spain., Van Cutsem E; University Hospitals Gasthuisberg Leuven and KU Leuven, Leuven, Belgium., Garralda E; START Madrid, Hospital Universitario HM Sanchinarro, Madrid, Spain., Tai D; Division of Medical Oncology, National Cancer Centre Singapore, Singapore., De Braud F; Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Geva R; Tel-Aviv Sourasky Medical Center, Tel-Aviv, Israel., van Bussel MTJ; Department of Clinical Pharmacology, The Netherlands Cancer Institute, Amsterdam, The Netherlands., Fiorella Dotti K; Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Elez E; Vall d'Hebron Barcelona Hospital Campus, Vall d'Hebron Institute of Oncology (VHIO), Universitat Autònoma de Barcelona, Barcelona, Spain., de Miguel MJ; START Madrid, Hospital Universitario HM Sanchinarro, Madrid, Spain., Litwiler K; Pfizer, Boulder, CO, USA., Murphy D; Pfizer, La Jolla, CA, USA., Edwards M; Pfizer, New York, NY, USA., Morris VK; Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Publikováno v: The oncologist [Oncologist] 2023 Mar 17; Vol. 28 (3), pp. 230-238.